細胞與基因治療製造服務市場－2026-2032年全球市場預測

預計到 2032 年，細胞和基因治療製造服務市場將成長至 494.2 億美元，複合年成長率為 16.45%。

主要市場統計數據
基準年 2025	170.1億美元
預計年份：2026年	197.5億美元
預測年份：2032年	494.2億美元
複合年成長率 (%)	16.45%

細胞和基因治療製造服務執行摘要

細胞和基因治療生產服務是先進醫療產品生態系統的核心，它推動自體和異體細胞療法、基於病毒載體的基因療法、基因修飾細胞產品以及基因組編輯計畫從臨床開發過渡到商業化供應。生物製藥的技術複雜性、嚴格的監管要求、低溫運輸要求、供體和患者的個體差異以及對檢驗、可重複且可擴展製程的需求，共同塑造了對專業合約開發和生產 (CDMO) 支援的需求。與傳統生技藥品不同，細胞和基因療法需要嚴格控制的工作流程，涵蓋細胞獲取、質體和病毒載體生產、轉導或基因編輯、細胞增殖、灌裝和精製、冷凍保存、分析測試、放行授權文件的準備以及身份管理（身份驗證鏈）或存儲歷史管理（監管鏈）。監管機構不斷完善化學、生產和品管(CMC)、等效性、療效測試、無菌保證和長期隨訪方面的指導方針，進一步強調品質源於設計 (QbD) 和可靠數據完整性的重要性。此外，腫瘤、罕見疾病、血液疾病、眼科和遺傳疾病領域獲準的先進療法數量不斷增加，以及利用 CAR-T、TCR-T、NK 細胞療法、造血幹細胞療法、AAV 載體、慢病毒載體和非病毒遞送平台的臨床研發管線不斷擴展，也推動了產業的蓬勃發展。對於製造商和申辦方而言，競爭力越來越取決於流程標準化、靈活的生產能力、自動化、分析深度、法規遵從性以及在確保患者安全和產品一致性的前提下縮短「從靜脈到靜脈」的前置作業時間。

細胞與基因治療製造的變革性變化

細胞和基因治療的生產環境正從高度人工化、以研發主導的方式向工業化轉型，充分利用數位技術，並採用以合規性為導向的營運模式。早期療法傳統上依賴開放式流程、客製化方案和小批量生產，但向後期臨床試驗和商業化供應的過渡，推動了對封閉式自動化系統、模組化潔淨室、一次性技術、標準化原料合格和可擴展載體生產的需求日益成長。自體細胞治療的生產在物流方面仍然要求很高，需要精確的排程、身分管理、低溫物流和快速放行檢測，因為每個批次都與特定患者相關聯。同時，異體細胞治療平台正在推動對物流批量生產、主細胞庫、供體篩檢、基因組編輯、免疫逃脫策略以及批次間可比性的投資。病毒載體的供應仍然是一個重要的技術瓶頸，特別是對於腺相關病毒（AAV）和慢病毒載體而言，因為在產量、全空衣殼表徵、雜質去除和分析標準化方面存在許多挑戰。非病毒遞送、轉座子系統、基於mRNA的編輯以及脂質奈米顆粒等技術也透過引入新的製程要求，對生產服務模式產生影響。監管審查正在加速CMC計劃、經驗證的療效指標、污染控制策略以及生命週期工藝驗證的製定。同時，分散式和照護現場生產的概念在時間緊迫的療法中日益受到關注，這需要統一的品質系統和數位化監控機制。這些變革正在重新思考服務供應商的選擇標準，申辦方現在優先考慮技術轉移能力、監管文件的品質、關鍵供應鏈的冗餘性以及在臨床和商業化生產中成熟的經驗。

人工智慧對製造業服務的累積影響

人工智慧 (AI) 正日益成為整體和基因治療生產服務中一股重要的驅動力，它能夠提升製程理解、預測控制、品質保證和營運效率。在上游和下游生產過程中，AI 模型可以分析來自反應器、細胞增殖平台、轉染實驗、純化系統和環境監測的高階製程數據，從而識別變異因素並提高批次間的一致性。機器學習技術在最佳化培養條件、預測細胞增殖和表現型、提高病毒載體產量以及支援製程變更後的可比性評估方面正變得越來越重要。在品管，AI 驅動的影像分析、流式細胞技術結果解讀、異常檢測和自動化生產記錄審查可以縮短產品上市時間，同時增強資料完整性（前提是系統經過驗證並符合良好生產規範 (GMP) 的要求）。 AI 還可以協助進行關鍵設備的預測性維護、安排患者特異性自體工作流程、原料需求計畫和低溫運輸風險管理。在高階分析領域，人工智慧有助於將關鍵程式參數與關鍵品質屬性關聯起來，從而改善功效檢測方法的開發，並支援更多基於證據的管理策略。然而，人工智慧的實施必須應對諸多挑戰，例如模型檢驗管治、可解釋性、網路安全、電子記錄合規性以及訓練資料集中的偏差。因此，人工智慧的整體影響並非取代生物製程專業知識，而是創造協同效應，促進品質源於設計 (QbD)、即時決策、偏差預防以及更具韌性的細胞和基因治療生產運作。

先進治療設備製造的關鍵區域洞察

亞太地區正迅速崛起為細胞和基因治療製造服務領域極為活躍的地區。這主要得益於臨床試驗活動的不斷拓展、政府主導的再生醫學舉措、醫院一體化創新中心的建立，以及中國、日本、韓國、澳洲、新加坡和印度等國在病毒載體、細胞處理和低溫基礎設施方面的投資。日本完善的再生醫學法規結構和韓國強大的生物技術製造能力正在推動該地區的應用，而中國的臨床研發管線和印度的生物製造人才儲備則為更廣泛的產能擴張提供了支持。歐洲擁有高度先進的治療藥物環境，在集中監管管道、強大的產學研合作、符合GMP標準的細胞處理、基因治療載體、品管檢測和醫院豁免框架等方面擁有成熟的專業知識。德國、法國、義大利、西班牙和英國在先進療法的臨床應用、監管科學、人才培養和製造標準方面都具有舉足輕重的地位。北美憑藉其緊密的臨床研究網路、成熟的監管合作關係、強大的大學附屬醫療中心、自體細胞療法、異體移植平台、質體DNA、病毒載體、分析檢測以及用於商業性化生產的完善的GMP基礎設施，仍然是全球先進療法研發的中心。美國主導區域發展，而加拿大則透過幹細胞研究、轉化醫學網路和專業生物製程技術做出貢獻。拉丁美洲正透過專注於腫瘤學的細胞療法研究、公私醫療合作以及法規結構的逐步完善而取得進展，其中巴西和墨西哥在臨床應用、醫院治療以及區域生產方面的討論中發揮著重要作用。非洲仍處於起步階段，但正透過其基因組醫學計畫、幹細胞研究、疫苗和生技藥品生產經驗以及協調監管和加強低溫運輸系統的努力來提升自身影響力——這些都是未來細胞和基因療法生產服務的重要基礎。在中東，對精準醫療、三級醫療和國家生物技術策略的投資正在增加。尤其是在海灣國家，醫療保健基礎設施和醫療創新計劃支持先進療法的準備、獲得專業治療、低溫物流以及先進療法製造能力的長期本地化。

細胞和基因治療製造的關鍵群體分析

儘管北約成員國並非醫療衛生貿易集團，但其中許多國家都將生物醫學安全放在首位，並擁有健全的供應鏈體系、先進的無菌生產基礎設施和完善的監管體系。隨著各國政府逐漸認知到細胞和基因療法生產、病毒載體供應、冷鏈物流以及生物製造冗餘是衛生安全和創新基礎設施的關鍵戰略組成部分，這些因素的重要性日益凸顯。七國集團（G7）憑藉其完善的監管機構、一流的學術醫療中心、先進的生物製藥基礎設施和活躍的臨床研究，仍然保持著強大的影響力。這些因素共同塑造了CM​​C文件、病人安全、藥物安全監測、生產品質以及先進療法商業化準備的全球標準。金磚國家（BRICS）則各具優勢。中國和印度擁有龐大的患者群體、不斷發展的生物技術生態系統以及擴大生產規模的潛力。巴西支持拉丁美洲的臨床和監管發展。俄羅斯在基因和細胞技術領域擁有強大的科學研究實力，而南非則是非洲生物醫學合作和能力建構的戰略中心。歐盟透過其集中核准機制、藥物安全監測要求、GMP標準、醫院豁免條款和跨境臨床研究，在先進治療藥物的監管協調方面發揮核心作用，並為標準化細胞和基因治療生產實踐提供了至關重要的環境。隨著新加坡、泰國、馬來西亞、印尼、越南和菲律賓加強其生物醫學研究、臨床試驗能力、監管現代化和低溫運輸基礎設施建設，東協在細胞和基因治療生產服務領域的重要性日益凸顯。新加坡是符合GMP標準的生物製程、人力資源發展和轉化醫學的區域中心。海灣合作理事會（GCC）正透過國家醫療衛生轉型計劃、對精準醫療的投資以及專業醫院網路的建設而發展壯大，該地區正逐步成為先進療法臨床應用、低溫物流、技術轉讓以及未來建立本地生產能力等夥伴關係的中心。

主要國家細胞和基因療法生產方面的趨勢

美國擁有細胞和基因治療生產服務領域最具活力的環境，這得益於其廣泛的臨床開發、完善的FDA生技藥品和先進療法監管管道、大學醫院網路，以及對CAR-T細胞療法、基因治療載體和基因組編輯平台商業化規模GMP生產能力的需求。中國是CAR-T細胞療法和基因治療研究及國內生產不斷擴張的主要成長中心，監管體係日益完善，臨床參與度也越來越高。印度憑藉其成本效益高的生物製造技術、不斷擴大的臨床研究以及對生物技術和再生醫學的政策重點，正取得顯著進展。德國在GMP生產、工業生物製程、醫院細胞療法和工程主導的自動化方面表現卓越，而英國憑藉其強大的臨床試驗基礎設施、專業的生產中心以及在先進治療藥物方面的監管經驗，仍然是細胞和基因治療實用化的領先中心。日本則充分利用其獨特的再生醫學框架、成熟的藥品品管系統以及對已通過核准的細胞衍生產品的早期應用。法國擁有先進的生物醫學研究、公共衛生基礎設施和細胞治療的專業知識，而加拿大則憑藉其在幹細胞科學、細胞治療實用化、生物製造培訓和合作研究基礎設施方面的既有優勢做出貢獻。巴西透過腫瘤學研究、再生醫學計畫以及不斷發展的先進療法法律規範，在拉丁美洲的活動中發揮核心作用。韓國以其強大的生物技術製造能力、幹細胞和免疫療法的開發以及政府對先進生物製藥創新的支持而聞名。澳洲透過臨床試驗、生物醫學研究機構以及與先進療法標準接軌的監管措施來支持這一領域。義大利和西班牙透過與醫院合作進行先進療法計畫、腫瘤學研究、符合GMP標準的細胞處理以及歐洲臨床網路做出貢獻。墨西哥正透過擴大臨床研究、接近性北美供應鏈以及投資醫療保健製造能力來增強其影響力。俄羅斯在基因技術和細胞醫學方面擁有強大的科學研究能力，但其國際合作和供應鏈可能會受到地緣政治限制的影響。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠降低變異性、增強監管信心並改善患者用藥可及性的生產策略，同時確保產品品質不受影響。申辦者和服務供應商應儘早進行CMC（化學、生產和控制）規劃，明確關鍵品質屬性（CQA）和關鍵程式參數（CPP），並在大規模製程變更或製造地搬遷前製定可比性策略。投資於封閉式、自動化、一次性使用的生產平台可以降低污染風險並提高可重複性，尤其是在內部工作流程中，因為在這些流程中，排程和身分控制至關重要。鑑於分析瓶頸常常限制臨床和商業性化應用，各組織應擴展其在效力、載體表徵、殘留雜質檢測、無菌性、黴漿菌和複製型病毒檢測以及快速放行方法方面的分析能力。應透過利用經認證的二級供應商提供質體、細胞激素、培養基、培養袋、過濾器、試劑和低溫物流，並對關鍵原料進行記錄在案的風險評估，來增強供應鏈的韌性。數位化製造執行系統、電子批次記錄、人工智慧驅動的偏差監控以及經過驗證的數據平台應整合到符合GMP規範的管治中。在病毒載體和基因組編輯專案中，領導者應著重於提高產量、實現可擴展的純化、進行全空衣殼分析、支持脫靶效應評估以及生命週期製程驗證。人才培養同樣至關重要。跨職能團隊需要具備無菌製程、細胞生物學、載體工程、品質保證、法規事務、自動化和低溫運輸運作等方面的專業知識。最後，全球製造網路需要平衡集中式專業知識與區域冗餘，以支持臨床試驗的連續性、商業化準備以及個人化療法的及時交付。

調查方法

本執行摘要採用結構化的二級研究方法編寫，重點關注從監管機構、臨床實驗室註冊機構、同行評審的科學期刊、公共衛生機構、標準化組織、行業指導文件和公開研究途徑資料中獲得的檢驗且有數據支持的行業證據。此調查方法強調定性整合，而非市場規模估算、計算、佔有率分析或預測。研究內容包括先進治療藥物和生技藥品的生產指導、GMP合規性、CMC（化學、生產和品管）預期、藥物安全監測、長期隨訪、無菌保證、病毒載體表徵和細胞治療過程。透過監管成熟度、臨床實驗室活動、研究基礎設施、生物製造能力、醫療保健系統發展、人才培養、低溫運輸能力以及對生物技術和再生醫學公共政策的支持等指標，評估區域和國家層面的具體情況。技術分析檢驗了生產平台、自動化、一次性系統、數位化品管工具、人工智慧應用、分析測試、冷凍保存和供應鏈管理。研究結果透過交叉引用多個可靠資訊來源進行檢驗，以識別一致的主題、營運限制和策略意義。研究過程中未使用任何公司聲明、檢驗的宣傳標語或推測性的財務預測。最終呈現的是基於證據的觀點，闡述了細胞和基因治療製造服務如何在不同的療法、地區、技術平台和法規環境下不斷發展演變。

結論

細胞和基因治療生產服務正成為全球向個人化、根治性和基因靶向醫療轉型過程中的關鍵能力。該領域的進展取決於能否應對諸多複雜挑戰，例如製程可擴展性、病毒載體生產、分析驗證、污染控制、身份驗證鏈管理以及監管文件。各區域的生態系發展成熟度不一。北美和歐洲已建立起管理體制和生產基礎設施；亞太地區正透過生物技術投資和臨床活動迅速擴張；新興地區則透過醫療現代化和研究合作建構基礎能力。人工智慧、自動化、封閉式流程和先進分析技術正在改變商業模式，但其價值取決於檢驗的實施方案、熟練的人員和健全的品質系統。那些將早期CMC（化學、生產和品管）體系、彈性供應鏈、高度可擴展的平台、強大的分析科學以及區域生產戰略相結合的行業領導者，在安全、穩定、及時地提供先進療法方面更具優勢。隨著臨床研發管線在癌症、罕見疾病、免疫系統疾病和遺傳性疾病等領域日益多元化，製造服務預計將繼續成為確保科學突破惠及病患的關鍵決定因素。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席主管觀點
• 市場規模和成長趨勢
• 新的商機
• 下一代經營模式
• 工業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 市場動態
• 波特五力分析
• PESTLE分析
• 市場展望
• 市場進入策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：細胞與基因治療製造服務市場：依服務類型分類

• GMP生產服務
  • 向量製造服務
  • 灌裝和精加工服務
• 流程開發服務
• 分析和品管服務
• 手機銀行服務
• 技術轉移服務
• 監理合規支援服務

第8章：細胞與基因治療製造服務市場：依製造流程分類

• 上游加工
  • 細胞分離
  • 細胞增殖
• 下游加工
  • 收藏
  • 純化
  • 配方

第9章：細胞與基因治療製造服務市場：依技術類型分類

• 基因編輯技術
  • CRISPR/Cas9
  • 轉錄活化因子樣效應核酸酶
  • 鋅指核酸酶
• 病毒載體平台
  • 慢病毒載體
  • 逆轉錄病毒載體
• 非病毒遞送系統
  • 質體DNA
  • 脂質奈米顆粒

第10章 細胞與基因治療製造服務市場：依細胞類型分類

• T細胞
• NK細胞
• 幹細胞
  • 造血幹細胞
  • 間質幹細胞
  • 誘導性多功能幹細胞
• 樹突狀細胞
• 巨噬細胞

第11章：細胞與基因治療製造服務市場：依交付模式分類

• Ex Vivo
• In Vivo

第12章：細胞與基因治療製造服務市場：依治療領域分類

• 心血管疾病
  • 缺血性心臟疾病
  • 心臟衰竭
• 感染疾病
  • B型肝炎
  • HIV
• 單基因疾病
  • 囊腫纖維化
  • 血友病
  • 鐮狀細胞貧血症
• 腫瘤學
  • 骨髓惡性腫瘤
  • 固體癌

第13章：細胞與基因治療製造服務市場：依應用領域分類

• 臨床生產
• 商業製造

第14章 細胞與基因治療製造服務市場：依最終用戶分類

• 受託研究機構
• 醫院和診所
• 製藥和生物技術公司
• 研究機構和學術機構

第15章 細胞與基因療法製造服務市場：按地區分類

• 亞太地區
• 歐洲
• 北美洲
• 拉丁美洲
• 非洲
• 中東

第16章：細胞與基因治療製造服務市場：依組別分類

• NATO
• G7
• BRICS
• EU
• ASEAN
• GCC

第17章 細胞與基因治療製造服務市場：依國家分類

• 美國
• 中國
• 印度
• 德國
• 英國
• 日本
• 法國
• 加拿大
• 巴西
• 韓國
• 澳洲
• 義大利
• 墨西哥
• 俄羅斯
• 西班牙

第18章 競爭格局

• 2025年市佔率分析
• FPNV定位矩陣，2025
• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年

第19章：公司簡介

• Thermo Fisher Scientific Inc.
• Lonza Group AG
• Charles River Laboratories International, Inc.
• CH Boehringer Sohn AG & Co. KG
• Merck KGaA
• Fujifilm Holdings Corporation
• Novartis AG
• Takara Bio Inc.
• Danaher Corporation
• WuXi AppTec Co., Ltd.
• Bio-Techne Corporation
• Catalent, Inc. by Novo Holdings A/S
• Recipharm AB
• AGC Biologics
• Advanced BioScience Laboratories, Inc.（Institut Merieux）
• Cell Therapies Pty Ltd.
• Cell-Easy
• eXmoor Pharma Concepts Limited
• Genezen Laboratories, Inc.
• Laboratory Corporation of America Holdings
• Miltenyi BIoTec BV & Co. KG
• Minaris Regenerative Medicine GmbH
• Nikon Corporation
• Oxford Biomedica PLC
• ProPharma Group Holdings, LLC
• Samsung Biologics Co., Ltd.
• SGS SA
• STEMCELL Technologies Inc.
• uBriGene Biosciences Inc.

The Cell & Gene Therapy Manufacturing Services Market is projected to grow by USD 49.42 billion at a CAGR of 16.45% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 17.01 billion
Estimated Year [2026]	USD 19.75 billion
Forecast Year [2032]	USD 49.42 billion
CAGR (%)	16.45%

Cell & Gene Therapy Manufacturing Services Executive Summary

Cell and gene therapy manufacturing services sit at the center of the advanced therapy medicinal products ecosystem, enabling the translation of autologous and allogeneic cell therapies, viral vector-based gene therapies, gene-modified cell products, and genome-editing programs from clinical development to commercial supply. Demand for specialized contract development and manufacturing support is being shaped by the technical complexity of living medicines, strict regulatory expectations, cold-chain requirements, donor and patient variability, and the need for validated, reproducible, and scalable processes. Unlike conventional biologics, cell and gene therapies require tightly controlled workflows across cell sourcing, plasmid and viral vector production, transduction or gene editing, cell expansion, fill-finish, cryopreservation, analytical testing, release documentation, and chain-of-identity or chain-of-custody management. Regulatory agencies have continued to refine guidance for chemistry, manufacturing, and controls; comparability; potency assays; sterility assurance; and long-term follow-up, reinforcing the importance of quality-by-design and robust data integrity. Industry momentum is also supported by the growing number of approved advanced therapies across oncology, rare diseases, hematology, ophthalmology, and inherited disorders, as well as expanding clinical pipelines using CAR-T, TCR-T, NK cell therapy, hematopoietic stem cell approaches, AAV vectors, lentiviral vectors, and non-viral delivery platforms. For manufacturers and sponsors, competitiveness increasingly depends on process standardization, flexible capacity, automation, analytical depth, regulatory readiness, and the ability to reduce vein-to-vein timelines while maintaining patient safety and product consistency.

Transformative Shifts in Cell & Gene Therapy Manufacturing

The cell and gene therapy manufacturing landscape is shifting from highly manual, research-driven production toward industrialized, digitally enabled, and compliance-centered operating models. Early-stage therapies have historically relied on open processing, bespoke protocols, and small-batch production, but the movement toward late-stage trials and commercial supply is increasing the need for closed and automated systems, modular cleanrooms, single-use technologies, standardized raw material qualification, and scalable vector manufacturing. Autologous cell therapy manufacturing remains logistically demanding because every batch is linked to an individual patient, requiring precise scheduling, identity management, cryogenic logistics, and rapid release testing. In parallel, allogeneic platforms are driving investment in larger-batch production, master cell banks, donor screening, genome editing, immune evasion strategies, and batch comparability. Viral vector supply remains a critical technical bottleneck, particularly for AAV and lentiviral vectors, due to challenges in yield, full-empty capsid characterization, impurity clearance, and analytical standardization. Non-viral delivery, transposon systems, mRNA-enabled editing, and lipid nanoparticle approaches are also influencing manufacturing service models by introducing alternative process requirements. Regulatory scrutiny is encouraging earlier CMC planning, validated potency assays, contamination-control strategies, and lifecycle process validation. At the same time, decentralized and point-of-care manufacturing concepts are gaining attention for time-sensitive therapies, though they require harmonized quality systems and digital oversight. These transformations are redefining service provider selection, with sponsors prioritizing technical transfer strength, regulatory documentation quality, redundancy in critical supply chains, and proven capabilities across clinical and commercial manufacturing.

Cumulative Impact of Artificial Intelligence on Manufacturing Services

Artificial intelligence is becoming a practical enabler across cell and gene therapy manufacturing services by improving process understanding, predictive control, quality assurance, and operational efficiency. In upstream and downstream manufacturing, AI-supported models can analyze high-dimensional process data from bioreactors, cell expansion platforms, transfection runs, purification systems, and environmental monitoring to identify drivers of variability and improve batch consistency. Machine learning methods are increasingly relevant for optimizing culture conditions, predicting cell growth and phenotype, improving viral vector yield, and supporting comparability assessments after process changes. In quality control, AI-enabled image analysis, flow cytometry interpretation, anomaly detection, and automated review of manufacturing records can shorten release timelines while strengthening data integrity, provided systems are validated and aligned with good manufacturing practice expectations. AI can also support predictive maintenance for critical equipment, scheduling of autologous patient-specific workflows, raw material demand planning, and cold-chain risk management. For advanced analytics, AI assists in linking critical process parameters to critical quality attributes, improving potency assay development and enabling more science-based control strategies. However, adoption must address validated model governance, explainability, cybersecurity, electronic record compliance, and bias in training datasets. The cumulative impact of artificial intelligence is therefore not a replacement for bioprocess expertise but a multiplier for quality-by-design, real-time decision-making, deviation prevention, and more resilient cell and gene therapy manufacturing operations.

Key Regional Insights Across Advanced Therapy Manufacturing

Asia-Pacific is emerging as a highly active region for cell and gene therapy manufacturing services, supported by expanding clinical trial activity, government-backed regenerative medicine initiatives, hospital-linked innovation hubs, and investments in viral vector, cell processing, and cryogenic infrastructure across China, Japan, South Korea, Australia, Singapore, and India. Japan's established regenerative medicine regulatory framework and South Korea's biotechnology manufacturing capabilities strengthen regional adoption, while China's clinical pipeline and India's biomanufacturing talent base support broader capacity development. Europe maintains a sophisticated advanced therapy medicinal products environment with centralized regulatory pathways, strong academic-industry collaboration, and established expertise in GMP cell processing, gene therapy vectors, quality control testing, and hospital exemption frameworks. Germany, France, Italy, Spain, and the United Kingdom are influential in clinical translation, regulatory science, workforce development, and manufacturing standards for advanced therapies. North America remains a global center for advanced therapy development due to a dense clinical research network, mature regulatory engagement, strong academic medical centers, and established GMP infrastructure for autologous cell therapy, allogeneic platforms, plasmid DNA, viral vectors, analytical testing, and commercial release. The United States leads regional activity, while Canada contributes through stem cell research, translational medicine networks, and specialized bioprocessing expertise. Latin America is progressing through oncology-focused cell therapy research, public-private healthcare collaboration, and gradual expansion of regulatory frameworks, with Brazil and Mexico playing visible roles in clinical adoption, hospital-based therapy delivery, and regional manufacturing discussions. Africa remains at an earlier stage but is building relevance through genomic medicine initiatives, stem cell research, vaccine and biologics manufacturing experience, and efforts to strengthen regulatory harmonization and cold-chain systems, which are essential foundations for future cell and gene therapy manufacturing services. The Middle East is increasing investment in precision medicine, tertiary care, and national biotechnology strategies, especially in Gulf economies where healthcare infrastructure and medical innovation programs are supporting advanced therapy readiness, specialized treatment access, cryogenic logistics, and long-term localization of advanced therapy manufacturing capabilities.

Key Group Insights for Cell & Gene Therapy Manufacturing

NATO countries, while not a healthcare trade bloc, include many nations with strong biomedical security priorities, resilient supply-chain initiatives, advanced sterile manufacturing infrastructure, and established regulatory systems; these factors are increasingly relevant as governments recognize cell and gene therapy manufacturing, viral vector supply, cryogenic logistics, and biomanufacturing redundancy as strategically important components of health security and innovation infrastructure. The G7 countries remain influential because of established regulatory authorities, leading academic medical centers, advanced biologics infrastructure, and high levels of clinical research activity, which collectively shape global standards for CMC documentation, patient safety, pharmacovigilance, manufacturing quality, and advanced therapy commercialization readiness. BRICS countries contribute diverse strengths: China and India provide large patient populations, growing biotechnology ecosystems, and manufacturing scale-up potential; Brazil supports Latin American clinical and regulatory development; Russia has scientific capacity in gene and cell technologies; and South Africa provides a strategic base for African biomedical collaboration and capacity building. The European Union plays a central role in harmonizing advanced therapy medicinal product regulation through centralized authorization mechanisms, pharmacovigilance requirements, GMP expectations, hospital exemption provisions, and cross-border clinical research, making the bloc a key environment for standardized cell and gene therapy manufacturing practices. ASEAN is gaining importance in cell and gene therapy manufacturing services as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines strengthen biomedical research, clinical trial capacity, regulatory modernization, and cold-chain readiness, with Singapore serving as a regional hub for GMP bioprocessing, talent development, and translational medicine. The GCC is advancing through national healthcare transformation programs, precision medicine investments, and specialized hospital networks, positioning the region for partnerships in advanced therapy clinical delivery, cryogenic logistics, technology transfer, and eventual localized manufacturing capabilities.

Key Country Insights in Cell & Gene Therapy Manufacturing

The United States is the most active national environment for cell and gene therapy manufacturing services, supported by extensive clinical development, FDA regulatory pathways for biologics and advanced therapies, academic medical center networks, and demand for commercial-scale GMP capacity in CAR-T, gene therapy vectors, and genome-editing platforms. China is a major growth center for CAR-T, gene therapy research, and domestic manufacturing expansion, with increasing regulatory sophistication and broad clinical participation. India is advancing through cost-efficient biomanufacturing expertise, expanding clinical research, and policy attention to biotechnology and regenerative medicine. Germany is prominent in GMP manufacturing, industrial bioprocessing, hospital-based cell therapy, and engineering-led automation, while the United Kingdom remains a major hub for cell and gene therapy translation, with strong clinical trial infrastructure, specialist manufacturing centers, and regulatory experience in advanced therapy medicinal products. Japan benefits from a distinctive regenerative medicine framework, mature pharmaceutical quality systems, and early adoption of approved cell-based products. France combines advanced biomedical research, public health infrastructure, and cell therapy expertise, while Canada contributes through recognized strengths in stem cell science, cell therapy translation, biomanufacturing training, and collaborative research infrastructure. Brazil anchors Latin American activity with oncology research, regenerative medicine programs, and evolving regulatory oversight for advanced therapies. South Korea is recognized for strong biotechnology manufacturing, stem cell and immune cell therapy development, and government support for advanced biopharmaceutical innovation. Australia supports the field through clinical trials, biomedical research institutes, and regulatory alignment with advanced therapy standards. Italy and Spain contribute through hospital-linked advanced therapy programs, oncology research, GMP cell processing, and European clinical networks. Mexico is developing relevance through clinical research growth, proximity to North American supply chains, and investment in healthcare manufacturing capabilities. Russia has scientific capabilities in genetic technologies and cellular medicine, though international collaboration and supply chains can be affected by geopolitical constraints.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize manufacturing strategies that reduce variability, strengthen regulatory confidence, and improve patient access without compromising product quality. Sponsors and service providers should engage CMC planning early, define critical quality attributes and critical process parameters, and build comparability strategies before major process changes or site transfers. Investment in closed, automated, and single-use manufacturing platforms can reduce contamination risk and support reproducibility, especially for autologous workflows where scheduling and chain-of-identity controls are essential. Organizations should expand analytical capabilities for potency, vector characterization, residual impurity testing, sterility, mycoplasma, replication-competent virus detection, and rapid release methods, since analytical bottlenecks often constrain clinical and commercial execution. Supply-chain resilience should be improved through qualified secondary suppliers for plasmids, cytokines, media, bags, filters, reagents, and cryogenic logistics, along with documented risk assessments for critical raw materials. Digital manufacturing execution systems, electronic batch records, AI-enabled deviation monitoring, and validated data platforms should be integrated under GMP-compliant governance. For viral vector and genome-editing programs, leaders should focus on yield improvement, scalable purification, full-empty capsid analytics, off-target assessment support, and lifecycle process validation. Workforce development is equally critical; cross-functional teams need expertise in aseptic processing, cell biology, vector engineering, quality assurance, regulatory affairs, automation, and cold-chain operations. Finally, global manufacturing networks should balance centralized expertise with regional redundancy to support clinical trial continuity, commercial readiness, and timely delivery of patient-specific therapies.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, data-backed industry evidence from regulatory agencies, clinical trial registries, peer-reviewed scientific publications, public health authorities, standards organizations, industry guidance documents, and publicly available policy resources. The methodology emphasizes qualitative synthesis rather than market estimation, sizing, share analysis, or forecasting. Research inputs include guidance on advanced therapy medicinal products, biologics manufacturing, GMP compliance, CMC expectations, pharmacovigilance, long-term follow-up, sterility assurance, viral vector characterization, and cell therapy processing. Regional and country insights are assessed through indicators such as regulatory maturity, clinical trial activity, research infrastructure, biomanufacturing capability, healthcare system readiness, workforce development, cold-chain capacity, and public policy support for biotechnology and regenerative medicine. Technology analysis reviews manufacturing platforms, automation, single-use systems, digital quality tools, AI applications, analytical testing, cryopreservation, and supply-chain controls. The findings are triangulated across multiple credible sources to identify consistent themes, operational constraints, and strategic implications. No proprietary company claims, unverified promotional statements, or speculative financial projections are used. The result is an evidence-oriented perspective on how cell and gene therapy manufacturing services are evolving across therapies, regions, technology platforms, and regulatory environments.

Conclusion

Cell and gene therapy manufacturing services are becoming a decisive capability in the global transition toward personalized, curative, and genetically targeted medicine. The sector's progress depends on solving complex challenges in process scalability, viral vector production, analytical validation, contamination control, chain-of-identity management, and regulatory documentation. Regional ecosystems are developing at different levels of maturity, with North America and Europe providing established regulatory and manufacturing depth, Asia-Pacific expanding rapidly through biotechnology investment and clinical activity, and emerging regions building foundational capabilities through healthcare modernization and research collaboration. Artificial intelligence, automation, closed processing, and advanced analytics are reshaping operational models, but their value depends on validated implementation, skilled personnel, and robust quality systems. Industry leaders that combine early CMC discipline, resilient supply chains, scalable platforms, strong analytical science, and regional manufacturing strategies will be better positioned to support safe, consistent, and timely delivery of advanced therapies. As clinical pipelines continue to diversify across oncology, rare diseases, immune disorders, and inherited conditions, manufacturing services will remain a critical determinant of whether scientific breakthroughs can reliably reach patients.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cell & Gene Therapy Manufacturing Services Market, by Service Type

• 7.1. Introduction
• 7.2. GMP Manufacturing Services
  • 7.2.1. Vector Production Services
  • 7.2.2. Fill & Finish Services
• 7.3. Process Development Services
• 7.4. Analytical & Quality Control Services
• 7.5. Cell Banking Services
• 7.6. Technology Transfer Services
• 7.7. Regulatory Support Services

8. Cell & Gene Therapy Manufacturing Services Market, by Manufacturing Process

• 8.1. Introduction
• 8.2. Upstream Processing
  • 8.2.1. Cell Isolation
  • 8.2.2. Cell Expansion
• 8.3. Downstream Processing
  • 8.3.1. Harvesting
  • 8.3.2. Purification
  • 8.3.3. Formulation

9. Cell & Gene Therapy Manufacturing Services Market, by Technology Type

• 9.1. Introduction
• 9.2. Gene Editing Technologies
  • 9.2.1. CRISPR/Cas9
  • 9.2.2. Transcription Activator-Like Effector Nucleases
  • 9.2.3. Zinc Finger Nucleases
• 9.3. Viral Vector Platforms
  • 9.3.1. Lentiviral Vectors
  • 9.3.2. Retroviral Vectors
• 9.4. Non-Viral Delivery Systems
  • 9.4.1. Plasmid DNA
  • 9.4.2. Lipid Nanoparticles

10. Cell & Gene Therapy Manufacturing Services Market, by Cell Type

• 10.1. Introduction
• 10.2. T Cells
• 10.3. NK Cells
• 10.4. Stem Cells
  • 10.4.1. Hematopoietic Stem Cells
  • 10.4.2. Mesenchymal Stem Cells
  • 10.4.3. Induced Pluripotent Stem Cells
• 10.5. Dendritic Cells
• 10.6. Macrophages

11. Cell & Gene Therapy Manufacturing Services Market, by Delivery Mode

• 11.1. Introduction
• 11.2. Ex Vivo
• 11.3. In Vivo

12. Cell & Gene Therapy Manufacturing Services Market, by Therapeutic Area

• 12.1. Introduction
• 12.2. Cardiovascular Diseases
  • 12.2.1. Coronary Artery Disease
  • 12.2.2. Heart Failure
• 12.3. Infectious Diseases
  • 12.3.1. Hepatitis B
  • 12.3.2. HIV
• 12.4. Monogenic Disorders
  • 12.4.1. Cystic Fibrosis
  • 12.4.2. Hemophilia
  • 12.4.3. Sickle Cell Anemia
• 12.5. Oncology
  • 12.5.1. Hematological Malignancies
  • 12.5.2. Solid Tumors

13. Cell & Gene Therapy Manufacturing Services Market, by Application

• 13.1. Introduction
• 13.2. Clinical Manufacturing
• 13.3. Commercial Manufacturing

14. Cell & Gene Therapy Manufacturing Services Market, by End-User

• 14.1. Introduction
• 14.2. Contract Research Organizations
• 14.3. Hospitals & Clinics
• 14.4. Pharmaceutical & Biotech Companies
• 14.5. Research Institutes & Academic Institutions

15. Cell & Gene Therapy Manufacturing Services Market, by Region

• 15.1. Asia-Pacific
• 15.2. Europe
• 15.3. North America
• 15.4. Latin America
• 15.5. Africa
• 15.6. Middle East

16. Cell & Gene Therapy Manufacturing Services Market, by Group

• 16.1. NATO
• 16.2. G7
• 16.3. BRICS
• 16.4. European Union
• 16.5. ASEAN
• 16.6. GCC

17. Cell & Gene Therapy Manufacturing Services Market, by Country

• 17.1. United States
• 17.2. China
• 17.3. India
• 17.4. Germany
• 17.5. United Kingdom
• 17.6. Japan
• 17.7. France
• 17.8. Canada
• 17.9. Brazil
• 17.10. South Korea
• 17.11. Australia
• 17.12. Italy
• 17.13. Mexico
• 17.14. Russia
• 17.15. Spain

18. Competitive Landscape

• 18.1. Market Share Analysis, 2025
• 18.2. FPNV Positioning Matrix, 2025
• 18.3. Market Concentration Analysis, 2025
  • 18.3.1. Concentration Ratio (CR)
  • 18.3.2. Herfindahl Hirschman Index (HHI)
• 18.4. Recent Developments & Impact Analysis, 2025
• 18.5. Product Portfolio Analysis, 2025
• 18.6. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Thermo Fisher Scientific Inc.
• 19.2. Lonza Group AG
• 19.3. Charles River Laboratories International, Inc.
• 19.4. C.H. Boehringer Sohn AG & Co. KG
• 19.5. Merck KGaA
• 19.6. Fujifilm Holdings Corporation
• 19.7. Novartis AG
• 19.8. Takara Bio Inc.
• 19.9. Danaher Corporation
• 19.10. WuXi AppTec Co., Ltd.
• 19.11. Bio-Techne Corporation
• 19.12. Catalent, Inc. by Novo Holdings A/S
• 19.13. Recipharm AB
• 19.14. AGC Biologics
• 19.15. Advanced BioScience Laboratories, Inc. by Institut Merieux
• 19.16. Cell Therapies Pty Ltd.
• 19.17. Cell-Easy
• 19.18. eXmoor Pharma Concepts Limited
• 19.19. Genezen Laboratories, Inc.
• 19.20. Laboratory Corporation of America Holdings
• 19.21. Miltenyi Biotec B.V. & Co. KG
• 19.22. Minaris Regenerative Medicine GmbH
• 19.23. Nikon Corporation
• 19.24. Oxford Biomedica PLC
• 19.25. ProPharma Group Holdings, LLC
• 19.26. Samsung Biologics Co., Ltd.
• 19.27. SGS S.A.
• 19.28. STEMCELL Technologies Inc.
• 19.29. uBriGene Biosciences Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, YEARS CONSIDERED FOR THE STUDY
• FIGURE 2. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, RESEARCH DESIGN
• FIGURE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, RESEARCH FRAMEWORK
• FIGURE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, DATA TRIANGULATION
• FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
• FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2025 VS 2032 (%)
• FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2032 (%)
• FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL TYPE, 2025 VS 2032 (%)
• FIGURE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
• FIGURE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
• FIGURE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
• FIGURE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
• FIGURE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
• FIGURE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
• FIGURE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
• FIGURE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

• TABLE 1. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION & COVERAGE
• TABLE 2. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL GMP MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL GMP MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL GMP MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL VECTOR PRODUCTION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL VECTOR PRODUCTION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL VECTOR PRODUCTION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL FILL & FINISH SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL FILL & FINISH SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL FILL & FINISH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL PROCESS DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL PROCESS DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL PROCESS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL ANALYTICAL & QUALITY CONTROL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL ANALYTICAL & QUALITY CONTROL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL ANALYTICAL & QUALITY CONTROL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL CELL BANKING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL CELL BANKING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL CELL BANKING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL TECHNOLOGY TRANSFER SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL TECHNOLOGY TRANSFER SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL TECHNOLOGY TRANSFER SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL REGULATORY SUPPORT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL REGULATORY SUPPORT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL REGULATORY SUPPORT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL UPSTREAM PROCESSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL UPSTREAM PROCESSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL UPSTREAM PROCESSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL CELL ISOLATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL CELL ISOLATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL CELL ISOLATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL CELL EXPANSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL CELL EXPANSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL CELL EXPANSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL DOWNSTREAM PROCESSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL DOWNSTREAM PROCESSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL DOWNSTREAM PROCESSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL HARVESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL HARVESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL HARVESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL PURIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL PURIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL PURIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL FORMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL FORMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL CRISPR/CAS9 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL CRISPR/CAS9 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL CRISPR/CAS9 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL ZINC FINGER NUCLEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL ZINC FINGER NUCLEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL ZINC FINGER NUCLEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL VIRAL VECTOR PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL VIRAL VECTOR PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL VIRAL VECTOR PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL LENTIVIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL LENTIVIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL LENTIVIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL RETROVIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL RETROVIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL RETROVIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL NON-VIRAL DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL NON-VIRAL DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL NON-VIRAL DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL PLASMID DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL PLASMID DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL PLASMID DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL T CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL T CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 84. GLOBAL T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 85. GLOBAL NK CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 86. GLOBAL NK CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 87. GLOBAL NK CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 88. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 89. GLOBAL STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 90. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 91. GLOBAL HEMATOPOIETIC STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 92. GLOBAL HEMATOPOIETIC STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 93. GLOBAL HEMATOPOIETIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 94. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 95. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 96. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 97. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 99. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 100. GLOBAL DENDRITIC CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 101. GLOBAL DENDRITIC CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 102. GLOBAL DENDRITIC CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 103. GLOBAL MACROPHAGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 104. GLOBAL MACROPHAGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 105. GLOBAL MACROPHAGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
• TABLE 107. GLOBAL EX VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 108. GLOBAL EX VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 109. GLOBAL EX VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL IN VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 111. GLOBAL IN VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 112. GLOBAL IN VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 113. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 114. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 115. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 116. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 117. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 118. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 119. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 120. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 121. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 122. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 123. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 124. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 125. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 126. GLOBAL HEPATITIS B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 127. GLOBAL HEPATITIS B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 128. GLOBAL HEPATITIS B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 129. GLOBAL HIV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 130. GLOBAL HIV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 131. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 132. GLOBAL MONOGENIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 133. GLOBAL MONOGENIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 134. GLOBAL MONOGENIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 135. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 136. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 137. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 138. GLOBAL HEMOPHILIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 139. GLOBAL HEMOPHILIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 140. GLOBAL HEMOPHILIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 141. GLOBAL SICKLE CELL ANEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 142. GLOBAL SICKLE CELL ANEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 143. GLOBAL SICKLE CELL ANEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 144. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 145. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 146. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 147. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 148. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 149. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 150. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 151. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 152. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 153. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 154. GLOBAL CLINICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 155. GLOBAL CLINICAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 156. GLOBAL CLINICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 157. GLOBAL COMMERCIAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 158. GLOBAL COMMERCIAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 159. GLOBAL COMMERCIAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 160. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
• TABLE 161. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 162. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 163. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 164. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 165. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 166. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 167. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 168. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 169. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 170. GLOBAL RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 171. GLOBAL RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 172. GLOBAL RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 173. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 174. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 175. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 176. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
• TABLE 177. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
• TABLE 178. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 179. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 180. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
• TABLE 181. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING TECHNOLOGIES, 2018-2032 (USD MILLION)
• TABLE 182. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR PLATFORMS, 2018-2032 (USD MILLION)
• TABLE 183. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
• TABLE 184. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
• TABLE 185. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
• TABLE 186. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
• TABLE 187. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 188. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 189. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 190. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 191. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 192. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 193. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
• TABLE 194. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 195. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 196. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
• TABLE 197. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
• TABLE 198. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 199. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 200. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
• TABLE 201. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING TECHNOLOGIES, 2018-2032 (USD MILLION)
• TABLE 202. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR PLATFORMS, 2018-2032 (USD MILLION)
• TABLE 203. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
• TABLE 204. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
• TABLE 205. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
• TABLE 206. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
• TABLE 207. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 208. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 209. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 210. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 211. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 212. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 213. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
• TABLE 214. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 215. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 216. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
• TABLE 217. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
• TABLE 218. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 219. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 220. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
• TABLE 221. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING TECHNOLOGIES, 2018-2032 (USD MILLION)
• TABLE 222. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR PLATFORMS, 2018-2032 (USD MILLION)
• TABLE 223. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
• TABLE 224. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
• TABLE 225. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
• TABLE 226. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
• TABLE 227. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 228. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 229. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 230. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 232. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
• TABLE 234. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 235. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 236. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
• TABLE 237. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
• TABLE 238. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 239. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 240. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
• TABLE 241. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING TECHNOLOGIES, 2018-2032 (USD MILLION)
• TABLE 242. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR PLATFORMS, 2018-2032 (USD MILLION)
• TABLE 243. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
• TABLE 244. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
• TABLE 245. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
• TABLE 246. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
• TABLE 247. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 248. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 249. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 250. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 252. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
• TABLE 254. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 255. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 256. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
• TABLE 257. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
• TABLE 258. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 259. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 260. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
• TABLE 261. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING TECHNOLOGIES, 2018-2032 (USD MILLION)
• TABLE 262. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR PLATFORMS, 2018-2032 (USD MILLION)
• TABLE 263. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
• TABLE 264. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
• TABLE 265. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
• TABLE 266. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
• TABLE 267. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 268. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 269. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 270. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 271. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 272. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 273. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
• TABLE 274. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 275. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 276. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
• TABLE 277. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
• TABLE 278. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 279. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 280. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
• TABLE 281. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING TECHNOLOGIES, 2018-2032 (USD MILLION)
• TABLE 282. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR PLATFORMS, 2018-2032 (USD MILLION)
• TABLE 283. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
• TABLE 284. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
• TABLE 285. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
• TABLE 286. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
• TABLE 287. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 288. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 289. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 290. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 291. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 292. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 293. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
• TABLE 294. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 295. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 296. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 297. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
• TABLE 298. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
• TABLE 299. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 300. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
• TABLE 301. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
• TABLE 302. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING TECHNOLOGIES, 2018-2032 (USD MILLION)
• TABLE 303. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR PLATFORMS, 2018-2032 (USD MILLION)
• TABLE 304. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
• TABLE 305. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
• TABLE 306. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
• TABLE 307. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
• TABLE 308. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 309. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 310. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 311. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 312. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 313. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 314. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
• TABLE 315. G7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 316. G7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 317. G7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
• TABLE 318. G7 CEL